

c-MET as a potential therapeutic target and biomarker in

Therapeutic Advances in Medical Oncology
3, S21-S35

DOI: [10.1177/1758834011422557](https://doi.org/10.1177/1758834011422557)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Frequent Gene Amplification Predicts Poor Prognosis in Gastric Cancer. <i>International Journal of Molecular Sciences</i> , 2012, 13, 4714-4726.	1.8	45
2	Antiangiogenic approaches for the treatment of advanced synovial sarcomas. <i>Current Opinion in Oncology</i> , 2012, 24, 425-430.	1.1	5
3	Pitfalls in Lung Cancer Molecular Pathology: How to Limit them in Routine Practice?. <i>Current Medicinal Chemistry</i> , 2012, 19, 2638-2651.	1.2	28
4	Metastatic gastric cancer – focus on targeted therapies. <i>Biologics: Targets and Therapy</i> , 2012, 6, 137.	3.0	25
5	Therapeutic potential of c-MET inhibitors: background and clinical data. <i>Clinical Investigation</i> , 2012, 2, 301-315.	0.0	1
6	Lung Cancer Genotype-Based Therapy and Predictive Biomarkers: Present and Future. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 1482-1491.	1.2	40
7	Vertical Pathway Targeting in Cancer Therapy. <i>Advances in Pharmacology</i> , 2012, 65, 1-26.	1.2	15
8	Macroporous hydrogel micropillars for quantifying Met kinase activity in cancer cell lysates. <i>Analyst</i> , The, 2012, 137, 4052.	1.7	7
9	Mechanisms of acquired resistance to targeted cancer therapies. <i>Future Oncology</i> , 2012, 8, 999-1014.	1.1	150
11	Celastrol exerts synergistic effects with PHA-665752 and inhibits tumor growth of c-Met-deficient hepatocellular carcinoma in vivo. <i>Molecular Biology Reports</i> , 2013, 40, 4203-4209.	1.0	26
12	Multiplexed tyrosine kinase activity detection in cancer cells using a hydrogel immobilized substrate. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 5489-5499.	1.9	3
13	HGF/c-met system targeting PI3K/AKT and STAT3/phosphorylated-STAT3 pathways in pituitary adenomas: an immunohistochemical characterization in view of targeted therapies. <i>Endocrine</i> , 2013, 44, 735-743.	1.1	38
14	Prognostic Value and Clinical Pathology of MACC-1 and c-MET Expression in Gastric Carcinoma. <i>Pathology and Oncology Research</i> , 2013, 19, 821-832.	0.9	30
15	New Advances in the Precision Medicine of Lung Cancer. <i>Current Pathobiology Reports</i> , 2013, 1, 1-8.	1.6	4
16	Crizotinib: A Review of Its Use in the Treatment of Anaplastic Lymphoma Kinase-Positive, Advanced Non-Small Cell Lung Cancer. <i>Drugs</i> , 2013, 73, 2031-2051.	4.9	70
17	Role of the Pulmonologist in Ordering Post-Procedure Molecular Markers in Non"Small-Cell Lung Cancer: Implications for Personalized Medicine. <i>Clinical Lung Cancer</i> , 2013, 14, 609-626.	1.1	15
18	Cell Surface Receptor Targeted Biomimetic Apatite Nanocrystals for Cancer Therapy. <i>Small</i> , 2013, 9, 3834-3844.	5.2	76
19	Lung Cancer Biomarkers: Present Status and Future Developments. <i>Archives of Pathology and Laboratory Medicine</i> , 2013, 137, 1191-1198.	1.2	105

#	ARTICLE	IF	CITATIONS
20	Understanding the functions of tumor stroma in resistance to ionizing radiation: Emerging targets for pharmacological modulation. <i>Drug Resistance Updates</i> , 2013, 16, 10-21.	6.5	36
21	High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer. <i>British Journal of Cancer</i> , 2013, 108, 1100-1105.	2.9	69
22	Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line. <i>Investigational New Drugs</i> , 2013, 31, 1158-1168.	1.2	22
23	Molecular Targeted Agents for Gastric Cancer: A Step Forward Towards Personalized Therapy. <i>Cancers</i> , 2013, 5, 64-91.	1.7	45
24	Role of cMET in the Development and Progression of Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2013, 14, 18056-18077.	1.8	47
25	Herbacetin, A Constituent of Ephedrae herba, Suppresses the HGF-Induced Motility of Human Breast Cancer MDA-MB-231 Cells by Inhibiting c-Met and Akt Phosphorylation. <i>Planta Medica</i> , 2013, 79, 1525-1530.	0.7	40
26	Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 925-936.	1.9	69
27	Anti-Epidermal Growth Factor Receptor Therapy in Head and Neck Squamous Cell Carcinoma: Focus on Potential Molecular Mechanisms of Drug Resistance. <i>Oncologist</i> , 2013, 18, 850-864.	1.9	82
28	KRAS Mutations as Prognostic and Predictive Markers in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 530-542.	0.5	104
29	Pubertal high fat diet: effects on mammary cancer development. <i>Breast Cancer Research</i> , 2013, 15, R100.	2.2	41
30	Expression of ST3GAL4 Leads to SLex Expression and Induces c-Met Activation and an Invasive Phenotype in Gastric Carcinoma Cells. <i>PLoS ONE</i> , 2013, 8, e66737.	1.1	96
31	Prognostic Significance of MET Amplification and Expression in Gastric Cancer: A Systematic Review with Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e84502.	1.1	80
32	Exploring the miRNA-mRNA Regulatory Network in Clear Cell Renal Cell Carcinomas by Next-Generation Sequencing Expression Profiles. <i>BioMed Research International</i> , 2014, 2014, 1-11.	0.9	36
33	Role of HGF-MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer. <i>Biomedicines</i> , 2014, 2, 345-358.	1.4	30
34	EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer. <i>Journal of Carcinogenesis & Mutagenesis</i> , 2014, 05, .	0.3	6
35	A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2014, 20, 6284-6294.	3.2	24
36	Targeting met mediated epithelial-mesenchymal transition in the treatment of breast cancer. <i>Clinical and Translational Medicine</i> , 2014, 3, 30.	1.7	20
37	Marine natural products-inspired phenylmethylene hydantoins with potent in vitro and in vivo antitumor activities via suppression of Brk and FAK signaling. <i>Organic and Biomolecular Chemistry</i> , 2014, 12, 5295-5303.	1.5	22

#	ARTICLE	IF	CITATIONS
38	Targeting c-Met in melanoma. <i>Cancer Biology and Therapy</i> , 2014, 15, 1129-1141.	1.5	39
39	New developments in the treatment of squamous cell lung cancer. <i>Current Opinion in Oncology</i> , 2014, 26, 152-158.	1.1	20
40	The Role of HGF/c-MET in Head and Neck Squamous Cell Carcinoma. , 2014, , 91-111.		1
41	Tumour growth stimulation following partial hepatectomy in mice is associated with increased upregulation of c-Met. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 1-14.	1.7	15
42	FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 464, 145-156.	1.4	51
43	MET Gene Copy Number Gain is an Independent Poor Prognostic Marker in Korean Stage I Lung Adenocarcinomas. <i>Annals of Surgical Oncology</i> , 2014, 21, 621-628.	0.7	17
44	Developing biomarkers to predict benefit from HGF/MET pathway inhibitors. <i>Journal of Pathology</i> , 2014, 232, 210-218.	2.1	35
45	Analysis of MET Genetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit. <i>Clinical Breast Cancer</i> , 2014, 14, 468-474.	1.1	29
46	New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial Designs. <i>Clinical Cancer Research</i> , 2014, 20, 4425-4435.	3.2	33
47	Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyridin-4-amine (Volitinib) as a Highly Potent and Selective Mesenchymal Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 7577-7589.	2.9	112
48	Activation of the Akt/mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors. <i>Cancer</i> , 2014, 120, 864-876.	2.0	29
49	HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma. <i>British Journal of Cancer</i> , 2014, 110, 1169-1178.	2.9	91
50	Frequent hepatocyte growth factor overexpression and low frequency of c-Met gene amplification in human papillomavirus-negative tonsillar squamous cell carcinoma and their prognostic significances. <i>Human Pathology</i> , 2014, 45, 1327-1338.	1.1	33
51	Complex renal cysts associated with crizotinib treatment. <i>Cancer Medicine</i> , 2015, 4, 887-896.	1.3	47
52	Targeting HGF/c-MET induces cell cycle arrest, DNA damage, and apoptosis for primary effusion lymphoma. <i>Blood</i> , 2015, 126, 2821-2831.	0.6	43
53	The three-way switch operation of Rac1/RhoA GTPase-based circuit controlling amoeboid-hybrid-mesenchymal transition. <i>Scientific Reports</i> , 2014, 4, 6449.	1.6	88
54	Differential expression of genes encoding proteins of the HGF/MET system in insulinomas. <i>Diabetology and Metabolic Syndrome</i> , 2015, 7, 84.	1.2	6
55	Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma. <i>Diseases (Basel, Switzerland)</i> , 2015, 3, 306-324.	1.0	9

#	ARTICLE	IF	CITATIONS
56	Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy. <i>Oncotarget</i> , 2015, 6, 24750-24779.	0.8	115
57	Recent advances in the HER2 targeted therapy of gastric cancer. <i>World Journal of Clinical Cases</i> , 2015, 3, 42.	0.3	39
58	Overexpression of FGFR2 contributes to inherent resistance to MET inhibitors in MET-amplified patient-derived gastric cancer xenografts. <i>Oncology Letters</i> , 2015, 10, 2003-2008.	0.8	11
59	The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0128159.	1.1	31
60	c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2015, 2, 29.	1.8	26
61	HGF-MET as a breast cancer biomarker. <i>Aging</i> , 2015, 7, 150-151.	1.4	9
62	Biomarkers for personalized medicine in GI cancers. <i>Molecular Aspects of Medicine</i> , 2015, 45, 14-27.	2.7	10
63	Targeting EGFR in lung cancer: Lessons learned and future perspectives. <i>Molecular Aspects of Medicine</i> , 2015, 45, 67-73.	2.7	42
64	MET/HGF pathway in multiple myeloma: from diagnosis to targeted therapy?. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 881-893.	1.5	14
65	Differential role of MACC1 expression and its regulation of the HGF/c-Met pathway between breast and colorectal cancer. <i>International Journal of Oncology</i> , 2015, 46, 2143-2153.	1.4	12
66	Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6. <i>International Journal of Oncology</i> , 2015, 47, 122-132.	1.4	34
67	Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment. <i>Oncogene</i> , 2015, 34, 144-153.	2.6	57
68	c-Met targeting in advanced gastric cancer: An open challenge. <i>Cancer Letters</i> , 2015, 365, 30-36.	3.2	67
69	Serum-based tracking of de novo initiated liver cancer progression reveals early immunoregulation and response to therapy. <i>Journal of Hepatology</i> , 2015, 63, 1181-1189.	1.8	11
70	Genomic aberrations guiding treatment of non-small cell lung cancer patients. <i>Cancer Treatment Communications</i> , 2015, 4, 23-33.	0.4	17
71	The clinical and functional significance of c-Met in breast cancer: a review. <i>Breast Cancer Research</i> , 2015, 17, 52.	2.2	146
72	The Ser/Thr kinase MAP4K4 drives c-Met-induced motility and invasiveness in a cell-based model of SHH medulloblastoma. <i>SpringerPlus</i> , 2015, 4, 19.	1.2	34
73	Glioblastoma multiforme: Pathogenesis and treatment. , 2015, 152, 63-82.		588

#	ARTICLE	IF	CITATIONS
74	Biomarkers and novel agents in esophago-gastric cancer: are we making progress?. Expert Review of Anticancer Therapy, 2015, 15, 1103-1119.	1.1	6
75	c-Met in esophageal squamous cell carcinoma: an independent prognostic factor and potential therapeutic target. BMC Cancer, 2015, 15, 451.	1.1	36
76	Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti-Hepatocyte Growth Factor Antibody Ficlatusumab. JAMA Otolaryngology - Head and Neck Surgery, 2015, 141, 1133.	1.2	43
77	Toward operative in vivo fluorescence imaging of the c-Met proto-oncogene for personalization of therapy in ovarian cancer. Cancer, 2015, 121, 202-213.	2.0	11
78	Neovascularization. Assessment in Esophageal Adenocarcinomas. Indian Journal of Surgery, 2015, 77, 971-976.	0.2	9
79	Contemporary treatment of metastatic renal cell carcinoma. Oncology Reviews, 2016, 10, 295.	0.8	32
80	A genetic database can be utilized to identify potential biomarkers for biphenotypic hepatocellular carcinoma-cholangiocarcinoma. Journal of Gastrointestinal Oncology, 2016, 7, 570-579.	0.6	7
81	Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection. OncoTargets and Therapy, 2016, Volume 9, 5825-5837.	1.0	25
82	Tyrosine kinase inhibitor SU11274 increased tumorigenicity and enriched for melanoma-initiating cells by bioenergetic modulation. BMC Cancer, 2016, 16, 308.	1.1	9
83	Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma. Molecular Carcinogenesis, 2016, 55, 2037-2050.	1.3	25
84	Polysialic acid sustains cancer cell survival and migratory capacity in a hypoxic environment. Scientific Reports, 2016, 6, 33026.	1.6	45
85	Molecular profiling of single circulating tumor cells from lung cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E8379-E8386.	3.3	90
86	Novel c-Met inhibitory olive secoiridoid semisynthetic analogs for the control of invasive breast cancer. European Journal of Medicinal Chemistry, 2016, 118, 299-315.	2.6	24
87	Molecular Signaling in Oral Cancer Invasion and Metastasis. , 2016, , 71-99.		1
88	Utilization of ancillary studies in the cytologic diagnosis of respiratory lesions: The papanicolaou society of cytopathology consensus recommendations for respiratory cytology. Diagnostic Cytopathology, 2016, 44, 1000-1009.	0.5	55
89	Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation. Molecular Cancer Therapeutics, 2016, 15, 3040-3054.	1.9	24
90	Cancer stem cells as a potential therapeutic target in thyroid carcinoma. Oncology Letters, 2016, 12, 2254-2260.	0.8	23
91	The renal effects of ALK inhibitors. Investigational New Drugs, 2016, 34, 643-649.	1.2	34

#	ARTICLE	IF	CITATIONS
92	Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) $\tilde{\text{A}}$ - c-MET Antibodies and Antibody-Drug Conjugates. <i>Journal of Biological Chemistry</i> , 2016, 291, 25106-25119.	1.6	66
93	Non-small cell lung cancer biomarkers and targeted therapy - two faces of the same coin fostered by nanotechnology. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 155-168.	0.4	8
94	Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives. <i>Tumor Biology</i> , 2016, 37, 127-140.	0.8	9
95	Allosteric inhibition of c-Met kinase in sub-microsecond molecular dynamics simulations induced by its inhibitor, tivantinib. <i>Physical Chemistry Chemical Physics</i> , 2016, 18, 10367-10374.	1.3	13
96	Design and synthesis of novel benzo[d]oxazol-2(3H)-one derivatives bearing 7-substituted-4-enthoxyquinoline moieties as c-Met kinase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2016, 115, 191-200.	2.6	14
97	Emerging therapeutic targets in metastatic progression: A focus on breast cancer. , 2016, 161, 79-96.		53
98	Targeted therapy in esophageal cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 595-604.	1.4	45
99	Novel strategy for a bispecific antibody: induction of dual target internalization and degradation. <i>Oncogene</i> , 2016, 35, 4437-4446.	2.6	26
100	Emerging Biomarkers in Personalized Therapy of Lung Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2016, 890, 25-36.	0.8	16
101	Targeting HER 2 and angiogenesis in gastric cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 111-122.	1.1	15
102	Predictive value of pAKT/PTEN expression in oral squamous cell carcinoma treated with cetuximab-based chemotherapy. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2016, 121, 67-72.	0.2	15
103	Regulation of HGF and c-MET Interaction in Normal Ovary and Ovarian Cancer: Importance of Targeting c-MET and HGF Interaction. <i>Reproductive Sciences</i> , 2017, 24, 494-501.	1.1	26
104	The Prognostic Significance of c-MET and EGFR Overexpression in Resected Gastric Adenocarcinomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 543-551.	0.6	9
105	The search for preoperative biomarkers for thyroid carcinoma: application of the thyroid circadian clock properties. <i>Biomarkers in Medicine</i> , 2017, 11, 285-293.	0.6	11
106	Dual inhibition using cabozantinib overcomes HGF/MET signaling mediated resistance to pan-VEGFR inhibition in orthotopic and metastatic neuroblastoma tumors. <i>International Journal of Oncology</i> , 2017, 50, 203-211.	1.4	27
107	Understanding c-MET signalling in squamous cell carcinoma of the head & neck. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 111, 39-51.	2.0	46
108	The c-Met receptor: Implication for targeted therapies in colorectal cancer. <i>Tumor Biology</i> , 2017, 39, 101042831769911.	0.8	42
109	AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis. <i>Oncology Reports</i> , 2017, 37, 2201-2208.	1.2	12

#	ARTICLE	IF	CITATIONS
110	MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 555-565.	1.9	129
111	Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 3195-3205.	1.4	19
112	MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1269-1278.	1.9	11
113	Norcantharidin Inhibits cell growth by suppressing the expression and phosphorylation of both EGFR and c-Met in human colon cancer cells. <i>BMC Cancer</i> , 2017, 17, 55.	1.1	40
114	Assessment of pharmacokinetic interaction between rilotumumab and epirubicin, cisplatin and capecitabine (ECX) in a Phase 3 study in gastric cancer. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1048-1055.	1.1	7
115	Cross-species analysis of the canine and human bladder cancer transcriptome and exome. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 328-343.	1.5	34
116	Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer?. <i>Cancer Treatment Reviews</i> , 2017, 61, 70-81.	3.4	62
117	Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 363, 136-147.	1.3	25
118	Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer. <i>Cancer Biology and Therapy</i> , 2017, 18, 694-704.	1.5	13
119	Simultaneous quantification of volitinib and gefitinib in rat plasma by HPLC-MS/MS for application to a pharmacokinetic study in rats. <i>Journal of Separation Science</i> , 2017, 40, 3782-3791.	1.3	6
120	Targeting c-MET in cancer therapy. <i>Chronic Diseases and Translational Medicine</i> , 2017, 3, 148-153.	0.9	128
121	Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 43-49.	1.1	31
122	Carcinoma associated fibroblasts derived from oral squamous cell carcinoma promote lymphangiogenesis via c-Met/PI3K/AKT in vitro. <i>Oncology Letters</i> , 2017, 15, 331-337.	0.8	16
123	Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma. <i>Cancers</i> , 2017, 9, 87.	1.7	53
124	MicroRNA-34a: A Key Regulator in the Hallmarks of Renal Cell Carcinoma. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-21.	1.9	35
125	Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4869-4883.	1.0	26
126	Expression of the c-MET, HGF and VEGF biomarkers in intestinal and diffuse gastric cancer in the Brazilian population: a pilot study for the standardization of the quantitative PCR technique. <i>Applied Cancer Research</i> , 2017, 37, .	1.0	0
127	Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment. <i>Cancers</i> , 2017, 9, 35.	1.7	85

#	ARTICLE	IF	CITATIONS
128	Real-time cellular and molecular dynamics of bi-metallic self-therapeutic nanoparticle in cancer cells. <i>Applied Nanoscience (Switzerland)</i> , 2018, 8, 115-124.	1.6	3
129	Redundant angiogenic signaling and tumor drug resistance. <i>Drug Resistance Updates</i> , 2018, 36, 47-76.	6.5	93
130	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2018, 13, 323-358.	0.5	408
131	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 321-346.	1.2	586
132	Supramolecular aptamer nano-constructs for receptor-mediated targeting and light-triggered release of chemotherapeutics into cancer cells. <i>Nature Communications</i> , 2018, 9, 535.	5.8	61
133	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 129-159.	1.2	241
134	Recent advances in the discovery of small molecule c-Met Kinase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2018, 143, 1103-1138.	2.6	116
135	One-step synthesis of [¹⁸ F]cabozantinib for use in positron emission tomography imaging of metastatic disease. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2018, 61, 11-17.	0.5	14
136	Prognostic Value of c-MET Expression in Patients With Pancreatic Cancer Receiving Adjuvant and Neoadjuvant Chemoradiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 490-497.	0.4	14
137	Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma. <i>Oncologist</i> , 2018, 23, 306-315.	1.9	56
138	miR-146a targets c-met and abolishes colorectal cancer liver metastasis. <i>Cancer Letters</i> , 2018, 414, 257-267.	3.2	45
139	Expression and Clinical Significance of Claudin-7, PDL-1, PTEN, c-Kit, c-Met, c-Myc, ALK, CK5/6, CK17, p53, EGFR, Ki67, p63 in Triple-negative Breast Cancer: A Single Centre Prospective Observational Study. <i>In Vivo</i> , 2018, 32, 303-311.	0.6	15
140	HGF/MET and the Immune System: Relevance for Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3595.	1.8	78
141	Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities. <i>Cellular Physiology and Biochemistry</i> , 2018, 51, 337-355.	1.1	14
142	MiR-140-5p suppresses retinoblastoma cell growth via inhibiting c-Met/AKT/mTOR pathway. <i>Bioscience Reports</i> , 2018, 38, .	1.1	29
143	Current Disease-Targets for Oleocanthal as Promising Natural Therapeutic Agent. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2899.	1.8	22
144	Boswellia frereana suppresses HGF-mediated breast cancer cell invasion and migration through inhibition of c-Met signalling. <i>Journal of Translational Medicine</i> , 2018, 16, 281.	1.8	13
145	Third line treatment of advanced oesophagogastric cancer: A critical review of current evidence and evolving trends. <i>Cancer Treatment Reviews</i> , 2018, 71, 32-38.	3.4	11

#	ARTICLE	IF	CITATIONS
146	The Role of Hepatocyte Growth Factor (HGF) in Insulin Resistance and Diabetes. <i>Frontiers in Endocrinology</i> , 2018, 9, 503.	1.5	70
147	Evaluation of the influence of green extraction solvents on the cytotoxic activities of <i>Crinum</i> (Amaryllidaceae) alkaloid extracts using in-vitro-in-silico approach. <i>Journal of Ethnopharmacology</i> , 2018, 227, 139-149.	2.0	16
148	The implications of TrkA and MET aberrations in de novo salivary duct carcinoma. <i>Human Pathology</i> , 2018, 81, 18-25.	1.1	8
149	A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers. <i>Investigational New Drugs</i> , 2018, 36, 886-894.	1.2	18
151	Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers. <i>Annals of Diagnostic Pathology</i> , 2018, 35, 69-76.	0.6	16
152	Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	61
154	Novel diagnostic techniques. , 2018, , 1-40.		1
155	The Heterogeneity of Lipid Metabolism in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1063, 33-55.	0.8	60
156	PET Imaging of Receptor Tyrosine Kinases in Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1625-1636.	1.9	35
157	Prognostic Significance of Mesenchymal-Epithelial Transition in Triple-Negative Breast Cancers. <i>Clinical Breast Cancer</i> , 2018, 18, e961-e966.	1.1	4
158	Current advances of targeting HGF/c-Met pathway in gastric cancer. <i>Annals of Translational Medicine</i> , 2018, 6, 247-247.	0.7	29
159	Targeting the Hepatocyte Growth Factor Receptor to Overcome Resistance to Targeted Therapies. , 2019, , 25-60.		2
160	Design, synthesis and biological evaluation of 6-substituted quinolines derived from cabozantinib as c-Met inhibitors. <i>Archiv Der Pharmazie</i> , 2019, 352, e1900101.	2.1	6
161	Curcumin as tyrosine kinase inhibitor in cancer treatment. <i>European Journal of Medicinal Chemistry</i> , 2019, 181, 111512.	2.6	66
162	Combination of Selected MET and EGFR Inhibitors Decreases Melanoma Cells' Invasive Abilities. <i>Frontiers in Pharmacology</i> , 2019, 10, 1116.	1.6	18
163	Validation of molecular biomarkers for preoperative diagnostics of human papillary thyroid carcinoma in fine needle aspirates. <i>Gland Surgery</i> , 2019, 8, S62-S76.	0.5	9
164	Investigational MET inhibitors to treat Renal cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 851-860.	1.9	19
165	Fendiline Enhances the Cytotoxic Effects of Therapeutic Agents on PDAC Cells by Inhibiting Tumor-Promoting Signaling Events: A Potential Strategy to Combat PDAC. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2423.	1.8	7

#	ARTICLE	IF	CITATIONS
166	Antitumor Activity of DFX117 by Dual Inhibition of c-Met and PI3K in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2019, 11, 627.	1.7	15
167	Phase I dose-escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors. <i>Cancer Science</i> , 2019, 110, 1340-1351.	1.7	33
168	A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591988900.	1.4	44
169	Olive Oil Phenols. , 0, , .		5
170	Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. <i>Cancers</i> , 2019, 11, 2033.	1.7	26
171	Towards dual inhibitors of the MET kinase and WNT signaling pathway; design, synthesis and biological evaluation. <i>RSC Advances</i> , 2019, 9, 37092-37100.	1.7	2
172	The Prognostic Role of MET Protein Expression Among Surgically Resected Non-small Cell Lung Cancer Patients: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 1441.	1.3	6
173	PIM1 kinase promotes cell proliferation, metastasis and tumor growth of lung adenocarcinoma by potentiating the c-MET signaling pathway. <i>Cancer Letters</i> , 2019, 444, 116-126.	3.2	27
174	Enhancing the Radiation Response in KRAS Mutant Colorectal Cancers Using the c-Met Inhibitor Crizotinib. <i>Translational Oncology</i> , 2019, 12, 209-216.	1.7	21
175	Effect of c-Met and CD44v6 Expression in Resistance to Chemotherapy in Esophageal Squamous Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 899-906.	0.7	9
176	TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors. <i>Molecular Oncology</i> , 2020, 14, 54-68.	2.1	39
177	Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?. <i>Frontiers in Oncology</i> , 2020, 10, 1642.	1.3	52
178	Design, synthesis and biological evaluation of novel 4-phenoxy pyridine based 3-oxo-3,4-dihydroquinoxaline-2-carboxamide derivatives as potential c-Met kinase inhibitors. <i>Biorganic Chemistry</i> , 2020, 105, 104371.	2.0	12
179	Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite. <i>Drug Metabolism and Disposition</i> , 2020, 48, 873-885.	1.7	25
180	Emerging role of phytochemicals in targeting predictive, prognostic, and diagnostic biomarkers of lung cancer. <i>Food and Chemical Toxicology</i> , 2020, 144, 111592.	1.8	19
181	Targeting HGF/c-MET Axis in Pancreatic Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9170.	1.8	35
182	A Review of the Ephedra genus: Distribution, Ecology, Ethnobotany, Phytochemistry and Pharmacological Properties. <i>Molecules</i> , 2020, 25, 3283.	1.7	50
183	Discovery of Novel c-Mesenchymal-Epithelia transition factor and histone deacetylase dual inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2020, 204, 112651.	2.6	10

#	ARTICLE	IF	CITATIONS
184	CAR T-cell therapy for triple-negative breast cancer: Where we are. <i>Cancer Letters</i> , 2020, 491, 121-131.	3.2	28
185	Molecular modelling study on pyrrolo[2,3- <i>b</i>]pyridine derivatives as c-Met kinase inhibitors: a combined approach using molecular docking, 3D-QSAR modelling and molecular dynamics simulation. <i>Molecular Simulation</i> , 2020, 46, 1265-1280.	0.9	6
186	The Novel Anti-cMet Antibody seeMet 12 Potentiates Sorafenib Therapy and Radiotherapy in a Colorectal Cancer Model. <i>Frontiers in Oncology</i> , 2020, 10, 1717.	1.3	4
187	Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a drug cocktail in patients with MET dysregulated advanced solid tumours: A phase I, multicentre, open-label, single-sequence drug-drug interaction study. <i>British Journal of Clinical Pharmacology</i> , 2020, 87, 2867-2878.	1.1	8
188	HGF/c-Met Axis: The Advanced Development in Digestive System Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 801.	1.8	10
189	Anti-neoplastic Effect of Ginkgolide C through Modulating c-Met Phosphorylation in Hepatocellular Carcinoma Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8303.	1.8	16
190	Synthesis and evaluation of ¹⁸ F labeled crizotinib derivative [¹⁸ F]FPC as a novel PET probe for imaging c-MET-positive NSCLC tumor. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115577.	1.4	15
191	Pancreatic ductal adenocarcinomas from Mexican patients present a distinct genomic mutational pattern. <i>Molecular Biology Reports</i> , 2020, 47, 5175-5184.	1.0	3
192	A dual MET/AXL small-molecule inhibitor exerts efficacy against gastric carcinoma through killing cancer cells as well as modulating tumor microenvironment. <i>MedComm</i> , 2020, 1, 103-118.	3.1	6
193	Expression of Insulin Receptor and c-MET Is Associated with Clinicopathologic Characteristics and Molecular Subtypes in Premenopausal Breast Cancer Patients. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 1614.	1.3	0
194	Large-Scale Virtual Screening Against the MET Kinase Domain Identifies a New Putative Inhibitor Type. <i>Molecules</i> , 2020, 25, 938.	1.7	7
195	Angiogenesis in Malignant Gliomas and Bevacizumab Resistance. , 2020, , .		0
196	c-Met as a potential therapeutic target in triple negative breast cancer. , 2020, , 295-326.		3
197	First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2020, 13, 6.	6.9	13
198	Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 147-156.	1.9	10
199	Synthesis and biological evaluation of quinoxaline derivatives as specific c-Met kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127189.	1.0	7
200	Peptide functionalized upconversion/NIR II luminescent nanoparticles for targeted imaging and therapy of oral squamous cell carcinoma. <i>Biomaterials Science</i> , 2021, 9, 1000-1007.	2.6	27
201	Enhancing Immunity with Nanomedicine: Employing Nanoparticles to Harness the Immune System. <i>ACS Nano</i> , 2021, 15, 7-20.	7.3	34

#	ARTICLE	IF	CITATIONS
202	c-Met-targeted near-infrared fluorescent probe for real-time depiction and dissection of perineural invasion and lymph node metastasis lesions in pancreatic ductal adenocarcinoma xenograft models. <i>Biomaterials Science</i> , 2021, 9, 6737-6752.	2.6	4
203	Mechanisms of Cetuximab Resistance and How to Overcome It. , 2021, , 21-51.		1
204	Regulation of Glycolysis in Head and Neck Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1280, 219-230.	0.8	3
205	Dnmt3b catalytic activity is critical for its tumour suppressor function in lymphomagenesis and is associated with c-Met oncogenic signalling. <i>EBioMedicine</i> , 2021, 63, 103191.	2.7	9
206	S-(α)-Oleocanthal as a c-Met receptor tyrosine kinase inhibitor and its application to synergize targeted therapies and prevent breast cancer recurrence. , 2021, , 681-691.		1
207	Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1330, 33-54.	0.8	3
208	Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes. <i>Advanced Therapeutics</i> , 2021, 4, 2000262.	1.6	9
209	cMet agonistic antibody prevents acute kidney injury to chronic kidney disease transition by suppressing Smurf1 and activating Smad7. <i>Clinical Science</i> , 2021, 135, 1427-1444.	1.8	3
210	Durable Response to Crizotinib in a Patient with Pulmonary Adenocarcinoma Harboring MET Intron 14 Mutation: A Case Report. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 3949-3958.	1.0	0
211	Effect of food on the single-dose pharmacokinetics and tolerability of savolitinib in Chinese healthy volunteers. <i>Fundamental and Clinical Pharmacology</i> , 2022, 36, 210-217.	1.0	5
212	The Level of Mesenchymal-Epithelial Transition Autophosphorylation is Correlated with Esophageal Squamous Cell Carcinoma Migration. <i>Iranian Biomedical Journal</i> , 2021, 25, 243-254.	0.4	0
213	Association between the HGF/c-MET signaling pathway and tumorigenesis, progression and prognosis of hepatocellular carcinoma (Review). <i>Oncology Reports</i> , 2021, 46, .	1.2	4
214	PrPC Regulates the Cancer Stem Cell Properties via Interaction With c-Met in Colorectal Cancer Cells. <i>Anticancer Research</i> , 2021, 41, 3459-3470.	0.5	7
215	Chimeric antigen receptor T-cells (CARs) in cancer treatment. <i>Current Molecular Pharmacology</i> , 2021, 14, .	0.7	1
216	Experience of treatment of a patient with non-small cell lung cancer with met exon 14 skipping. <i>Meditsinskiy Sovet</i> , 2021, , 154-159.	0.1	1
217	Docking and dynamic simulation study of Crizotinib and Temozolomide drug with Glioblastoma and NSCLC target to identify better efficacy of the drug. <i>Future Journal of Pharmaceutical Sciences</i> , 2021, 7, .	1.1	5
218	The Heterogeneity of Lipid Metabolism in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1311, 39-56.	0.8	27
219	Targeting c-Met and AXL Crosstalk for the Treatment of Hepatocellular Carcinoma. , 2021, , 333-364.		0

#	ARTICLE	IF	CITATIONS
220	Two-Temperature Formalin Fixation Preserves Activation States Efficiently. <i>Recent Results in Cancer Research</i> , 2015, 199, 107-117.	1.8	2
221	Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts. <i>Cancer Science</i> , 2020, 111, 536-547.	1.7	44
222	Microvesicles Derived from Human Wharton's Jelly Mesenchymal Stem Cells Promote Human Renal Cancer Cell Growth and Aggressiveness through Induction of Hepatocyte Growth Factor. <i>PLoS ONE</i> , 2014, 9, e96836.	1.1	77
223	Targeted Co-Delivery of Docetaxel and cMET siRNA for Treatment of Mucin1 Overexpressing Breast Cancer Cells. <i>Advanced Pharmaceutical Bulletin</i> , 2018, 8, 383-393.	0.6	22
224	Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation. <i>Oncotarget</i> , 2016, 7, 57651-57670.	0.8	29
225	Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib. <i>Oncotarget</i> , 2016, 7, 72622-72633.	0.8	60
226	Transcriptional upregulation of c-MET is associated with invasion and tumor budding in colorectal cancer. <i>Oncotarget</i> , 2016, 7, 78932-78945.	0.8	36
227	Molecular mechanisms of activating c-MET in KSHV+ primary effusion lymphoma. <i>Oncotarget</i> , 2017, 8, 18373-18380.	0.8	5
228	Anti-proliferative role of recombinant lethal toxin of <i>Bacillus anthracis</i> on primary mammary ductal carcinoma cells revealing its therapeutic potential. <i>Oncotarget</i> , 2017, 8, 35835-35847.	0.8	7
229	NFE2L2/NRF2 silencing-inducible miR-206 targets c-MET/EGFR and suppresses BCRP/ABCG2 in cancer cells. <i>Oncotarget</i> , 2017, 8, 107188-107205.	0.8	26
230	Therapeutic effect of a TM4SF5-specific monoclonal antibody against colon cancer in a mouse model. <i>Oncotarget</i> , 2014, 5, 8402-8415.	0.8	11
231	Crizotinib Exhibits Antitumor Activity by Targeting ALK Signaling not c-MET in Pancreatic Cancer. <i>Oncotarget</i> , 2014, 5, 9150-9168.	0.8	21
232	Co-expression of MET and CD47 is a novel prognosticator for survival of luminal-type breast cancer patients. <i>Oncotarget</i> , 2014, 5, 8147-8160.	0.8	83
233	Gefitinib or lapatinib with foretinib synergistically induce a cytotoxic effect in melanoma cell lines. <i>Oncotarget</i> , 2018, 9, 18254-18268.	0.8	21
234	MET overexpression and activation favors invasiveness in a model of anaplastic thyroid cancer. <i>Oncotarget</i> , 2019, 10, 2320-2334.	0.8	11
235	Identification of new biomarkers for human papillary thyroid carcinoma employing NanoString analysis. <i>Oncotarget</i> , 2015, 6, 10978-10993.	0.8	24
236	The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitor. <i>Oncotarget</i> , 2016, 7, 32247-32273.	0.8	18
237	Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling. <i>Oncotarget</i> , 2016, 7, 29492-29506.	0.8	29

#	ARTICLE	IF	CITATIONS
238	Potential roads for reaching the summit: an overview on target therapies for high-grade gliomas. <i>Acta Biomedica</i> , 2020, 91, 61-78.	0.2	12
239	c-Met signaling in the development of tumorigenesis and chemoresistance: Potential applications in pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 8458.	1.4	56
240	Clinical management of advanced gastric cancer: The role of new molecular drugs. <i>World Journal of Gastroenterology</i> , 2014, 20, 14537.	1.4	41
241	Gastric cancer patient with c-MET amplification treated with crizotinib after failed multi-line treatment: A case report and literature review. <i>Mathematical Biosciences and Engineering</i> , 2019, 16, 5923-5930.	1.0	11
242	c-MET expression in colorectal adenomas and primary carcinomas with its corresponding metastases. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 618-27.	0.6	25
243	Prognostic and predictive value of MET deregulation in non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2015, 3, 83.	0.7	25
244	The hallmarks of cancer and their therapeutic targeting in current use and clinical trials. <i>Iraqi Journal of Hematology</i> , 2020, 9, 1.	0.0	6
245	c-Met as a Target for Personalized Therapy. <i>Translational Oncogenomics</i> , 2015, Suppl. 1, 13-31.	1.7	102
246	Prevalence and Clinicopathological Significance of MET Overexpression and Gene Amplification in Patients with Gallbladder Carcinoma. <i>Cancer Research and Treatment</i> , 2020, 52, 481-491.	1.3	11
247	Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3653-3664.	1.2	19
248	Molecular Targeted Therapies in Pancreatic Cancer. , 2013, , 117-144.		0
249	Treatment Strategies for KRAS Mutated Non-small Cell Lung Cancer. , 2015, , 157-185.		0
250	c-MET in Head and Neck Squamous Cell Carcinoma. <i>Current Cancer Research</i> , 2018, , 63-88.	0.2	1
251	Clinical and Pathological Value of MACC-1 Expression in Gastric Carcinoma. <i>Journal of Cancer Therapy</i> , 2019, 10, 609-618.	0.1	0
252	Molecular mechanisms of resistance to monoclonal antibodies therapy patients with squamous cell carcinoma of the tongue and mucosa of the oral cavity. <i>Malignant Tumours</i> , 2019, 8, 13-25.	0.1	1
253	Targeting Tyrosine-protein Kinase Receptor (c-MET) Gene Alterations in Non-small Cell Lung Cancer – The Efficacy and Safety of Tepotinib + Gefitinib in the INSIGHT Study. <i>European Oncology and Haematology</i> , 2019, 15, 86.	0.0	0
254	Hepatocyte Growth Factor and Macrophage-stimulating Protein –Hinge–Analogues to Treat Pancreatic Cancer. <i>Current Cancer Drug Targets</i> , 2019, 19, 782-795.	0.8	1
255	⁶⁸ Ga-EMP-100 PET/CT –a novel ligand for visualizing c-MET expression in metastatic renal cell carcinoma –first in-human biodistribution and imaging results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1711-1720.	3.3	15

#	ARTICLE	IF	CITATIONS
256	Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents. <i>Annals of Translational Medicine</i> , 2015, 3, 81.	0.7	9
258	Antibody-Drug Conjugates: Possibilities and Challenges. <i>Avicenna Journal of Medical Biotechnology</i> , 2019, 11, 3-23.	0.2	83
259	c-MET expression potentially contributes to the poor prognosis of rhabdomyosarcoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2018, 11, 4083-4092.	0.5	4
260	Targeted Treatment of Non-Small Cell Lung Cancer: Focus on Capmatinib with Companion Diagnostics. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 5321-5331.	1.0	4
261	Hydrogen/Deuterium Exchange Mass Spectrometry with Integrated Electrochemical Reduction and Microchip-Enabled Deglycosylation for Epitope Mapping of Heavily Glycosylated and Disulfide-Bonded Proteins. <i>Analytical Chemistry</i> , 2021, 93, 16330-16340.	3.2	17
262	Human telomerase reverse transcriptase promotes the epithelial to mesenchymal transition in lung cancer cells by enhancing c-MET upregulation. <i>Heliyon</i> , 2022, 8, e08673.	1.4	3
263	Cancer immunomodulation using bispecific aptamers. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 27, 894-915.	2.3	20
264	Hepatocyte Growth Factor Overexpression Slows the Progression of 4NQO-Induced Oral Tumorigenesis. <i>Frontiers in Oncology</i> , 2021, 11, 756479.	1.3	0
265	SRC kinase activator CDCP1 promotes hepatocyte growth factor-induced cell migration/invasion of a subset of breast cancer cells. <i>Journal of Biological Chemistry</i> , 2022, 298, 101630.	1.6	4
266	The Emerging Role of c-Met in Carcinogenesis and Clinical Implications as a Possible Therapeutic Target. <i>Journal of Oncology</i> , 2022, 2022, 1-12.	0.6	23
267	Genomic profiling of gallbladder carcinoma: Targetable mutations and pathways involved. <i>Pathology Research and Practice</i> , 2022, 232, 153806.	1.0	4
268	Recent progress in the imaging of c-Met aberrant cancers with positron emission tomography. <i>Medicinal Research Reviews</i> , 2022, 42, 1588-1606.	5.0	12
270	Role of Cytokines and Chemokines in Angiogenesis in a Tumor Context. <i>Cancers</i> , 2022, 14, 2446.	1.7	32
271	PET Imaging of Lung Cancers in Precision Medicine: Current Landscape and Future Perspective. <i>Molecular Pharmaceutics</i> , 2022, 19, 3471-3483.	2.3	4
272	Pharmacological Targeting of Epithelial-to-Mesenchymal Transition in Colorectal Cancer. <i>Current Pharmaceutical Design</i> , 2022, 28, 2298-2311.	0.9	7
273	Treatment of Metastatic Melanoma with a Combination of Immunotherapies and Molecularly Targeted Therapies. <i>Cancers</i> , 2022, 14, 3779.	1.7	18
274	Crizotinib attenuates cancer metastasis by inhibiting TGF β ² signaling in non-small cell lung cancer cells. <i>Experimental and Molecular Medicine</i> , 2022, 54, 1225-1235.	3.2	3
275	Effect of capmatinib on the pharmacokinetics of substrates of CYP3A (midazolam) and CYP1A2 (caffeine) in patients with MET-dysregulated solid tumours. <i>British Journal of Clinical Pharmacology</i> , 0, , .	1.1	0

#	ARTICLE	IF	CITATIONS
276	Positron emission tomography imaging of lung cancer: An overview of alternative positron emission tomography tracers beyond F18 fluorodeoxyglucose. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
277	Medicinal and Therapeutic Properties of Ephedra. <i>Revista Brasileira De Farmacognosia</i> , 2022, 32, 883-899.	0.6	2
278	Tumorigenesis Mechanisms Found in Hereditary Renal Cell Carcinoma: A Review. <i>Genes</i> , 2022, 13, 2122.	1.0	7
279	Targeted Delivery Polymeric Nanosystem Reinforced by Synergism of Embilin and RPI-1 for Therapeutics of Pancreatic Cancer. <i>ACS Applied Nano Materials</i> , 2022, 5, 18622-18636.	2.4	1
280	Expression of c-MET in Estrogen Receptor Positive and HER2 Negative Resected Breast Cancer Correlated with a Poor Prognosis. <i>Journal of Clinical Medicine</i> , 2022, 11, 6987.	1.0	2
281	Engineering c-Met-CAR NK-92 cells as a promising therapeutic candidate for lung adenocarcinoma. <i>Pharmacological Research</i> , 2023, 188, 106656.	3.1	9
282	The Behaviour of Cancers: Invasion and Metastasis II. <i>Experimental Analysis of Mechanisms</i> . , 2023, , 175-227.		0
283	<i>Preksha Dhyāna</i> Meditation Effect on the DNA Methylation Signature in College Students. , 2023, 29, 224-233.		1
285	Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry. <i>Archives of Pharmacal Research</i> , 2023, 46, 131-148.	2.7	18
287	Approved and investigational fluorescent optical imaging agents for disease detection in surgery. <i>International Journal of Surgery</i> , 2023, 109, 2378-2387.	1.1	1
290	Molecular testing in lung cancer. , 2024, , 319-337.		0
291	Chemokine and Cytokine Network in Angiogenesis. , 2023, , 79-114.		0
295	c-Met Receptor PET Imaging Probes for Cancer Detection and Monitoring. , 2024, , .		0